VIATRIS INC. Repayments of Long-Term Debt
VIATRIS INC. (VTRS) reported Repayments of Long-Term Debt of $2.23 billion for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Financing Activities
us-gaap:RepaymentsOfLongTermDebt · last filed 2026-08-06
- VIATRIS INC. repayments of long-term debt for the quarter ending 2025-12-31 was $100.00K, a 99.99% decline year-over-year.
- VIATRIS INC. repayments of long-term debt for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- VIATRIS INC. repayments of long-term debt for the quarter ending 2024-12-31 was $1.37B, a 174.81% increase year-over-year.
- VIATRIS INC. repayments of long-term debt for the quarter ending 2024-09-30 was $1.54B.
- VIATRIS INC. repayments of long-term debt for fiscal 2025 was $100.00K, a 100.00% decline from fiscal 2024.
- VIATRIS INC. repayments of long-term debt for fiscal 2024 was $3.71B, a 197.05% increase from fiscal 2023.
- VIATRIS INC. repayments of long-term debt for fiscal 2023 was $1.25B, a 65.86% decline from fiscal 2022.
- VIATRIS INC. repayments of long-term debt for fiscal 2022 was $3.66B, a 12.82% decline from fiscal 2021.
| Period end | Repayments of Long-term Debt 3 month | Repayments of Long-term Debt 6 month | Repayments of Long-term Debt 9 month | Repayments of Long-term Debt 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.23B 10-Q · filed 2026-08-06 | |||
| 2025-12-31 | $100.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $100.00K derived: sum of 2 quarters · filed 2026-02-26 | $100.00K 10-K · filed 2026-02-26 | |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $0.00 10-Q · filed 2025-11-06 | ||
| 2025-06-30 | $0.00 10-Q · filed 2026-08-06 | |||
| 2024-12-31 | $1.37B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $2.91B derived: sum of 2 quarters · filed 2026-02-26 | $3.71B derived: sum of 3 quarters · filed 2026-02-26 | $3.71B 10-K · filed 2026-02-26 |
| 2024-09-30 | $1.54B derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $2.34B derived: sum of 2 quarters · filed 2025-11-06 | $2.34B 10-Q · filed 2025-11-06 | $2.84B derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $801.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $801.70M 10-Q · filed 2025-08-07 | $1.30B derived: sum of 3 quarters · filed 2026-02-26 | $1.30B derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $0.00 10-Q · filed 2024-05-09 | $500.10M derived: sum of 2 quarters · filed 2026-02-26 | $500.10M derived: sum of 3 quarters · filed 2026-02-26 | $500.10M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $500.10M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $500.10M derived: sum of 2 quarters · filed 2026-02-26 | $500.10M derived: sum of 3 quarters · filed 2026-02-26 | $1.25B 10-K · filed 2026-02-26 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $0.00 derived: sum of 2 quarters · filed 2024-11-07 | $750.10M 10-Q · filed 2024-11-07 | $1.45B derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $750.10M 10-Q · filed 2024-08-08 | $1.45B derived: sum of 3 quarters · filed 2025-02-27 | $2.63B derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $750.10M 10-Q · filed 2024-05-09 | $1.45B derived: sum of 2 quarters · filed 2025-02-27 | $2.63B derived: sum of 3 quarters · filed 2025-02-27 | $4.41B derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $700.60M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $1.88B derived: sum of 2 quarters · filed 2025-02-27 | $3.66B derived: sum of 3 quarters · filed 2025-02-27 | $3.66B 10-K · filed 2025-02-27 |
| 2022-09-30 | $1.17B derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $2.96B derived: sum of 2 quarters · filed 2023-11-08 | $2.96B 10-Q · filed 2023-11-08 | $2.96B derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | $1.79B derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | $1.79B 10-Q · filed 2023-08-07 | $1.79B derived: sum of 3 quarters · filed 2024-02-28 | $3.74B derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | $100.00K 10-Q · filed 2023-05-08 | $700.00K derived: sum of 2 quarters · filed 2024-02-28 | $1.95B derived: sum of 3 quarters · filed 2024-02-28 | $4.20B derived: sum of 4 quarters · filed 2024-02-28 |
| 2021-12-31 | $600.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $1.95B derived: sum of 2 quarters · filed 2024-02-28 | $4.20B derived: sum of 3 quarters · filed 2024-02-28 | $4.20B 10-K · filed 2024-02-28 |
| 2021-09-30 | $1.95B derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | $4.20B derived: sum of 2 quarters · filed 2022-11-07 | $4.20B 10-Q · filed 2022-11-07 | $6.10B derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-06-30 | $2.25B derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $2.25B 10-Q · filed 2022-08-08 | $4.15B derived: sum of 3 quarters · filed 2023-02-27 | $4.15B derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-03-31 | $0.00 10-Q · filed 2022-05-09 | $1.90B derived: sum of 2 quarters · filed 2023-02-27 | $1.90B derived: sum of 3 quarters · filed 2023-02-27 | $2.45B derived: sum of 4 quarters · filed 2023-02-27 |
| 2020-12-31 | $1.90B derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $1.90B derived: sum of 2 quarters · filed 2023-02-27 | $2.45B derived: sum of 3 quarters · filed 2023-02-27 | $2.48B 10-K · filed 2023-02-27 |
| 2020-09-30 | -$100.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | $555.90M derived: sum of 2 quarters · filed 2021-11-08 | $588.90M 10-Q · filed 2021-11-08 | |
| 2020-06-30 | $556.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $589.00M 10-Q · filed 2021-08-09 | ||
| 2020-03-31 | $33.00M 10-Q · filed 2021-05-10 | |||
| 2019-12-31 | $1.11B 10-K · filed 2022-02-28 | |||
| 2018-12-31 | $3.17B 10-K · filed 2021-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |